Bridie Anderson-Fahey

Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.

Journal of Psychopharmacology October 2017 Paul Glue, Natalie J. Medlicott, Sarah Harland et al.

The N-methyl-D-aspartate receptor antagonist ketamine has rapid onset activity in treatment-resistant depression, post-traumatic stress disorder and obsessive compulsive disorder. Due to similarities in brain network activity in depression and anxiety disorders, we hypothesized that ketamine might also be active in other refractory anxiety disorders. We evaluated the efficacy and safety of...